Crosswalk Therapeutics announced it has secured a research grant from the National MPS Society to support early development of a next generation enzyme based therapy for Morquio A syndrome. The rare inherited disorder is caused by deficiency of the GALNS enzyme and leads to progressive skeletal and connective tissue disease. Existing enzyme replacement therapies face challenges reaching bone and cartilage, limiting their impact on the most debilitating aspects of disease progression in affected patients worldwide over long clinical timelines today.
The funded program will support proof of concept studies for a fusion protein designed to enhance enzyme performance and improve delivery to skeletal tissues. The approach targets biological barriers that constrain current treatments and uses computational design to refine molecular properties while maintaining preclinical rigor. Although initially focused on Morquio A, the strategy may inform therapies for other lysosomal storage disorders with similar tissue access challenges. Grant support from the National MPS Society reflects growing emphasis on patient focused innovation addressing areas of persistent unmet need. Crosswalk plans to apply the findings to guide future development decisions and potential partnerships as the company explores scalable therapeutic platforms aligned with rare disease regulatory pathways and long term clinical translation goals globally.
Why it matters
Targeted funding can accelerate development of therapies addressing skeletal disease gaps that current treatments fail to resolve in rare disorders.
Source Attribution
Source: Crosswalk Therapeutics
